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The neuropeptide Y (NPY) system is a multireceptor/multiligand system consisting of four
receptors in humans (hY1, hY2, hY4, hY5) and three agonists (NPY, PYY, PP) that activate
these receptorswith different potency.The relevance of this system in diseases like obesity
or cancer, and the different role that each receptor plays inﬂuencing different biological
processes makes this system suitable for the design of subtype selectivity studies. In
this review we focus on the latest ﬁndings within the NPY system, we summarize
recent mutagenesis studies, structure activity relationship studies, receptor chimera, and
selective ligands focusing also on the binding mode of the native agonists.
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INTRODUCTION TO THE NEUROPEPTIDE Y FAMILY
The neuropeptide Y (NPY) family is a multireceptor/multiligand
system consisting of four receptors in humans and three polypep-
tides that bind and activate them with different afﬁnity and
potency. The NPY receptors belong to the class A or rhodopsin-
like G-protein coupled receptors (GPCR). Five receptors have
been cloned from mammals so far, Y1, Y2, Y4, Y5, and y6 but
only four of the members are functional in humans (hY1, hY2,
hY4, hY5; Table 1). The y6 receptor however is active in rabbit
and mouse (Starback et al., 2000). The existence of an additional
receptor subtype (Y3) was suggested by pharmacological studies
of several human, rat, and rabbit tissues including the human
adrenal medulla. This receptor subtype is characterized by amuch
lower afﬁnity for PYY, compared to NPY (Gehlert, 1998; Lee and
Miller, 1998). However, since all attempts to clone this receptor
subtype were unsuccessful so far, the existence of Y3 is not very
likely.
Neuropeptide Y receptors (NPYR) generally couple to Gi or
G0 proteins, which leads to the inhibition of adenylate cyclase and
ﬁnally to the inhibition of cAMPaccumulation (Cabrele andBeck-
Sickinger, 2000) and modulation of Ca2+ and K+ channels (Holl-
iday et al., 2004). Besides this, it has been described that Y2 and Y4
receptors also couple to the Gq protein increasing inositol 1,4,5-
phosphate (IP3) production via the activation of the phospholi-
pase C-β (PLC) in rabbit smooth muscle cells (Misra et al., 2004).
Neuropeptide Y, peptide YY (PYY), and pancreatic polypep-
tide (PP) are the native ligands of the NPY family. NPY is the
most abundant peptide in the mammalian brain and has been
suggested to adopt a largely open structure. In surface association
with phospholipidmicelles a ﬂexibleN-terminus and aC-terminal
alpha helix were identiﬁed (Lerch et al., 2004; Parker et al., 2011).
However, PYY and PP are suggested to form the typical hairpin-
like structure also called PP-fold, a suggestion for pPYY supported
by NMR (Keire et al., 2000a; Neumoin et al., 2007), and for PP by
the X-ray structure of the peptide (Blundell et al., 1981). Despite
some structural differences between the ligands, these polypep-
tides have a common length of 36 amino acids (Table 2) and an
amidatedC-terminus. Furthermore, these polypeptides share high
sequence identity. Whereas NPY and PYY show the highest per-
centage of common residues with 70%, NPY and PP share only
50% identity (Blomqvist et al., 1992; Zhang et al., 2011). Seven
positions in NPY, PYY, and PP are strongly conserved throughout
all species: Pro5, Pro8, Gly9, Ala12, Tyr27, Arg33, and Arg35. Apart
from these, highly conserved positions are: Pro2, Tyr20, Thr32, and
Tyr36 (Cabrele and Beck-Sickinger, 2000). Regarding its pharma-
cological properties, NPY acts as a neurotransmitter whereas PYY
and PP act as neuroendocrine hormones.
The ﬁrst identiﬁed member of the family PP, was isolated from
avian pancreas in 1975 (Kimmel et al., 1975). This polypeptide is
secreted in the pancreas by PP cells in the Langerhans islets after
food ingestion in proportion to the caloric content (Boguszewski
et al., 2010; Suzuki et al., 2010). It is thought to act mainly in
brain stemandvagal nervewhere it promotes appetite suppression,
inhibition of gastric emptying and increases in energy expenditure
(Asakawa et al., 2003) in addition to direct responses in the gut.
The secondmember of the ligand family PYY,was isolated from
porcine intestinal extracts in 1980 (Tatemoto andMutt, 1980) and
is expressed by entero-endocrine L cells of the distal gut (Lundberg
et al., 1982). PYY1−36 is released in proportion to nutrient intake
along the gut and cleaved to PYY3−36 by the dipeptidyl aminopep-
tidase VI. The ligand PYY3−36, the predominant form released in
the circulation, is selective forY2 and produces anorexigenic effects
(Pittner et al., 2004). This polypeptide acts on peripheral recep-
tors but also on those located in the CNS (Hankir et al., 2011;
Schloegl et al., 2011). The last family member, NPY, was isolated
fromporcine brain in 1982 (Tatemoto,1982) and is oneof themost
broadly distributed peptides of the central and peripheral nervous
system. This peptide is well conserved among different species.
It stimulates food intake in response to negative energy balance
(Stanley et al., 1986). Additional roles of NPY are decreased bone
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Table 1 | Amino acid sequence of the NPY ligands.
Peptides Amino acid sequence
1 5 10 15 20 25 30 35
pNPY Y P S K P D N P G E D A P A E D L A R Y Y S A L R H Y I N L I T R Q R Y
hPYY Y P I K P E A P G E D A S P E E L N R Y Y A S L R H Y L N L V T R Q R Y
hPP A P L E P V Y P G D N A T P E Q M A Q Y A A D L R R Y I N M L T R P R Y
Table 2 | NPYR: sequence length and ligand preference.
Receptor hY1 hY2 hY4 hY5
Amino acids number 384 381 375 445–455
Native ligand NPY NPY PP NPY
PYY PYY PYY
formation (Baldock et al., 2009; Sousa et al., 2012), regulation of
mood and anxiety disorders, the modulation of stress responses
(Heilig, 2004), and ethanol intake (Thiele et al., 1998).
Neuropeptide Y family peptides mediate their activity in
humans via four receptors. Structurally, these receptors contain
two Cys residues in the extracellular regions that form a disul-
ﬁde bond between extracellular loop I and II. This disulﬁde bond
is a common feature of class A GPCRs and has been conﬁrmed
by X-ray crystallography for several members including bovine
rhodopsin and the human β2 adrenergic receptor (Palczewski
et al., 2000; Cherezov et al., 2007).
The evolution of this system shows that vertebrate ancestors
probably had three receptor genes. These genes, possibly located
in close proximity in the same chromosomal segment, would
be the precursors of the receptor subfamilies. The Y1 subfamily
includes the Y1, Y4, and y6 receptors, the Y2 subfamily comprises
Y2 and Y7 (in zebraﬁsh and frogs), and the Y5 subfamily con-
sists of only the Y5 due to lack of close relatives of this receptor
(Larhammar and Salaneck,2004). Although theY1 andY2 receptor
subtypes have a common pharmacological proﬁle, they only share
27% of sequence identity. Y1 and y6 receptors share the highest
sequence identity (51%), whereas Y1 and Y4 receptors share 44%
identity, increasing to 56% identity in transmembrane regions
(Larhammar et al., 2001). The Y4 receptor conserves 75% of over-
all identity between human and rat suggesting this protein may
be the most rapidly evolving member of the family and the only
member that has a selective agonist, the pancreatic polypeptide
(Larhammar, 1996; Blomqvist and Herzog, 1997). The Y5 recep-
tor displays low sequence identity, around 30%, with all members
of the family. Compared with other GPCRs, neuropeptide Y
receptors share a high sequence identity with NPFF1 and NPFF2
receptors, which are members of the RFamide receptor family
(Bonini et al., 2000).
The Y1 receptor has 384 amino acids and its main agonists
are NPY and PYY. It can be also activated by PP with a minor
potency (Table 2). The receptor is expressed in the hypothala-
mus, hippocampus, neocortex, and thalamus (Caberlotto et al.,
1997), but is also present in adipose tissue (Castan et al., 1993;
Hausman et al., 2008), blood vessels (Cabrele and Beck-Sickinger,
2000), colon, kidney, adrenal gland, heart, and placenta (Whar-
ton et al., 1993). It plays a role in the regulation of food intake
(Kanatani et al., 2000b), vasoconstriction of blood vessels (Cabrele
and Beck-Sickinger, 2000), heart rate, anxiety (Balasubramaniam,
2002), and bone homeostasis (Sousa et al., 2012).
The Y2 receptor is predominantly expressed in hippocam-
pal neurons, in the thalamus, hypothalamus, and parts of the
peripheral nervous system (Widdowson, 1993; Cabrele and Beck-
Sickinger, 2000). It is mainly found in pre-synaptic neurons and
exerts its action through the regulation of neurotransmitter release
(Wahlestedt et al., 1986; Potter et al., 1989). Typical effects corre-
lated with activation of this receptor include enhanced memory
retention, the regulation of the circadian rhythm, angiogenesis
(Flood and Morley, 1989; Golombek et al., 1996; Gribkoff et al.,
1998; Zukowska-Grojec et al., 1998) and bone formation (Baldock
et al., 2002). This receptor consists of 381 amino acids and its
preferred agonists are NPY and PYY (Table 2).
The Y4 receptor subtype is the only member of the family
with the endogenous agonist PP, while PYY and NPY can still
activate this receptor with minor potency (Table 2). It consists
of 375 amino acids and is mainly expressed in the gastrointesti-
nal tract (Lundell et al., 1995; Ferrier et al., 2002) but also in the
brain (Bard et al., 1995), as well as pancreas and prostate (Lundell
et al., 1995). It plays a role in the regulation of feeding (Asakawa
et al., 1999; Sainsbury et al., 2010), circadian ingestion and energy
homeostasis (Edelsbrunner et al., 2009), colonic transit (Moriya
et al., 2010), and stimulation of the luteinizing hormone release
(Jain et al., 1999).
The Y5 receptor subtype is expressed in two different splice
variants, composed of 445 and 455 amino acids, respectively
(Table 1). The N-terminus of the longer isoform is extended by
10 amino acids. However, these differences in the sequence of the
receptor isoforms do not result in differences in their pharma-
cological proﬁle (Rodriguez et al., 2003). Both receptor isoforms
bind NPY and PYY with comparable afﬁnities. The afﬁnity for PP
is slightly lower, but still in the nanomolar range (Gerald et al.,
1996). Y5 receptors are mainly expressed in the central nervous
system. Tissues with high receptor density include the hippocam-
pus and hypothalamus. The Y5 receptor subtype has been shown
to be strongly involved in food intake (Gerald et al., 1996). Other
possible roles of the Y5 receptor are the regulation of the cir-
cadian rhythm (Matsumoto et al., 1996b; Gribkoff et al., 1998)
and reproduction through inhibition of LH release (Raposinho
et al., 2001).
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The y6 receptor encodes a 371 amino acid protein that has been
cloned from rabbit, mouse, and chicken among others (Bromee
et al., 2006). However, the sequence in humans and monkeys con-
tains a frame shiftmutation in the third intracellular loop, resulting
in a non-functional truncated receptor protein (Matsumoto et al.,
1996a; Michel et al., 1998).
Taken together, this multireceptor/multiligand system medi-
ates many relevant physiological and pathological processes. This
makes the NPY family truly attractive for the design of sub-
type selective analogs and receptors. Even if selective ligands are
pharmacologically the most attractive approach to tackle subtype
selectivity, development of receptor chimeras or receptor mutants
will also help to understand how the receptors reﬁned their bind-
ing pockets during evolution and, as a result, will show how the
ligands tend to have distinct afﬁnities for one or the other receptor
subtype.
DEVELOPING SELECTIVE LIGANDS FOR NPY RECEPTORS
As it has been previously described, the binding afﬁnity of each
peptide differs from receptor to receptor and the role that each
receptor plays in regulating physiological processes is different. In
light of this, the NPY system is a perfect candidate in which to
develop selective ligands and selective receptors to modulate these
characteristics.
GENERAL STRATEGIES
The most conventional way of investigating subtype selectivity is
the synthesis of selective ligands. Consequently, to obtain subtype
selective ligands, the peptides have to be modiﬁed in key posi-
tions allowing the investigator to modulate the ligand preference
for a receptor. Although the peptides of the NPY family share
high sequence homology, they do not necessarily have the same
binding mode. The truncation of certain fragments can direct
the selectivity to a certain receptor subtype providing information
about essential fragments of the peptide. Therefore, one of the
approaches to investigate important positions on the peptides are
N- or C- terminal truncations.
Another approach to investigate subtype selectivity is the
alanine-scan or Ala-scan: this means that each residue in the
sequence is one by one individually substituted with Ala. When
an Ala occurs naturally in a certain position, this residue is then
changed to Gly. In this scan, only the functional groups are substi-
tuted permitting the investigation of ionic interactions as well as
dipole-dipole and hydrophobic interactions. Once all the analogs
are synthesized they must be tested at all the receptor subtypes to
determine how the substitution of the native amino acid affects
the binding or the activation. In case a residue shows a great loss
in binding or activation for a certain receptor, further exchanges
in this position can be done. For example the exchange of a cer-
tain residue of NPY by the residue present in PP can achieve Y4
receptor binding with the analog. The use of D-amino acids in a
scan can provide information about the side chain orientation and
steric information concerning ligand binding too, Pro-scans reveal
favorable turn-structures and Phe-scans hydrophobic interactions
(Lindner et al., 2008a).
As small peptides can adopt several active conformations and
these conformations can be recognized by different receptor
subtypes in structure-activity relationships, the knowledgeof these
binding subtypes is of great interest. Furthermore, to investigate
the binding mode and receptor preference of small antagonists
or non-peptidic drugs, knowledge of the bioactive conformation
is of major importance. Constraining the ligand conformation
and testing the peptide on several receptor subtypes, can pro-
vide information about its bioactive conformation and receptor
selectivity. Several strategies can be used to investigate structure
activity relationships constraining the conformation of small pep-
tides (Beck-Sickinger, 1997). First of all, non-proteinogenic amino
acids can be incorporated, reducing the number of angle combina-
tions that anatural amino acid could adopt, and therebydecreasing
the ﬂexibility of the peptide. One example of a non-proteinogenic
amino acid is Aib (aminoisobutyric acid). This residue is one the
most commonly used in this kind of study. Secondly, the use of
several templates and amino acid linkers to induce a desired con-
formation might be also a good strategy, although this does not
always lead to the desired effect because of other amino acids
within the sequence. The use of more ﬂexible linkers such as
Ahx (6-aminohexanoic acid) or ω-amino alkanoic acids might
be a better method to determine the distance between two seg-
ments. Finally, the use of cyclization can signiﬁcantly constrain
the conformation of a ligand. Several cyclization techniques can
be applied, the most commonly used are: cyclization by disulﬁde
formation between two Cys residues, cyclization by lactamization
of N- and/or C-terminus or by the N- and C-group-containing
side chains Lys, Orn, Dab, Asp, and Glu and backbone to side-
chain cyclization. Recent studies also use click reactions to cyclize
peptides using triazoles to mimic disulﬁde bridges (Holland-Nell
and Meldal, 2011) and peptide stapling to increase the propensity
to formα-helices, therefore improvingpharmacological properties
(Verdine andWalensky, 2007).
Y1 RECEPTOR
N-/C-terminal truncations of NPY conﬁrm the importance of
these two segments for Y1 receptor binding. N-terminally trun-
cated analogs are notwell accepted by theY1 receptor as canbe seen
in studies using the shortened sequences NPY(3–36), (13–36), and
(18–36). These show only micromolar afﬁnities for this receptor
and even the truncation of the ﬁrst amino acid NPY(2–36), results
in a loss of afﬁnity (Beck-Sickinger and Jung, 1995). C-terminal
truncations show the importance of the amide group in the bind-
ing with the receptor (Hoffmann et al., 1996). Centrally truncated
analogs containing the spacer Ahx and structurally constrained
analogs showed that the N- and C-terminal fragments must have
a certain length to bind with a good afﬁnity to the receptor (Kirby
et al., 1993b). Furthermore, using an Ala-scan it was found that,
Pro2, Pro5, Arg19, and Tyr20 are important for ligand afﬁnity. Also
the amino acids from positions 27 to 36 were found to be crucial
for the peptide, especially position 27. Moreover, positions 33 and
35 showed to be extremely important, as Ala analogs at these posi-
tions produced a dramatic loss in binding of >5000-fold over wt
(Figure 3; Beck-Sickinger et al., 1994; Cabrele and Beck-Sickinger,
2000; Lindner et al., 2008b). The importance of Arg35 was further
conﬁrmed as this residue was found to form a subtype-speciﬁc
ionic interaction with Asp6.59 of the receptor (Merten et al., 2007).
The Tyr on position 36 was also found to be relevant for the ligand
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binding; this position does however tolerate the exchange to Phe,
but not Ala, Bpa, or His. Similar results were obtained using a
D-amino acid scan (Kirby et al., 1993a).
Positions 7, 25, 26, 31, and 34 were revealed to be important for
subtype selectivity (Figure 1A). Modiﬁcations in positions 25 and
26 showed that [D-Arg25]NPY and [D-His26]NPY bind selectively
to the Y1 receptor (Mullins et al., 2001). Also the introduction of
Pro in position 34, present in pancreatic polypeptide, redirected
the afﬁnity of the peptide to Y1/Y5 receptors. Apart from Gln34,
an additional exchange in Asn7 introducing Phe at this position,
a similar residue like the Tyr present on the hPP, yielded [Phe7,
Pro34]pNPY. This is a selective Y1 receptor binder and illustrated
the importance of an aromatic residue in this position (Soll et al.,
2001). Also the combination of Pro34 with an exchange in posi-
tion 31 by Leu contributes to aY1/Y4/Y5receptor selective proﬁle
(Fuhlendorff et al., 1990; Cabrele et al., 2000). All this strongly
indicates the importance of N- and C-terminal fragments for the
Y1 receptor subtype.
The synthesis of small selective ligands has also been a topic
of interest in the past years and many peptides have been synthe-
sized and characterized. Although theﬁrst experimentswith short-
or medium-sized pNPY truncations showed low binding afﬁnity
at the hY1 receptor, in recent years several short antagonists,
mimicking the NPY C-terminus have been synthesized such as,
GR231118 (1229U91 or GW1229), T-241, and T-190. Unfortu-
nately, these ligands also have Y4 agonistic properties (Figure 2;
Parker et al., 1998). Taking the short NPY analog NPY (28–36)
and the antagonist GR231118, Zwanziger et al. (2009) designed
a set of 19 short peptide analogs. Only [Pro30, Nle31, Bpa32,
Leu34]NPY(28–36) displayed hY1 receptor selectivity andwas able
to activate the receptor (Figure 1B). Follow-up investigations were
made by Hofmann and colleagues (Neuropeptides, accepted) on
position 32. The authors could further stabilize the peptide by
replacing Bpa by Bip (biphenylalanine) and could switch the activ-
ity from hY1 receptor to hY2/hY4 receptors by introducing an
ortho-carbaboranyl moiety. Other small peptide antagonists are
BW1911U90 and [32−34βACC]-NPY(25–36)]; Figure 2; Koglin
et al., 2003), and examples of known non-peptidic antagonists are
BIBP3226, BIBO3304, LY357897, J-104870 (Figure 4A; Rudolf
et al., 1994; Hipskind et al., 1997;Wieland et al., 1998; Sjodin et al.,
2006; Antal-Zimanyi et al., 2008).
Y2 RECEPTOR
As with the human Y1 receptor, the Y2 receptor binds NPY and
PYY with comparable afﬁnities. Beside these two native high-
afﬁnity ligands, a number of Y2-selective NPY-derived peptide
FIGURE 1 | Important amino acid positions and truncated peptides to
introduce selectivity to NPY receptors. (A) Important positions in pNPY
(Fuhlendorff et al., 1990; Cabrele et al., 2000, 2002; Parker et al., 2000;
Mullins et al., 2001; Soll et al., 2001); (B)Truncations of pNPY (Beck et al.,
1989; Fournier et al., 1994; Beck-Sickinger and Jung, 1995; Keire et al., 2000b;
Zwanziger et al., 2009). (C) Important positions in hPP (Schwartz, 2006).
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FIGURE 2 | Peptidic antagonists of theY1 receptor (Parker et al., 1998; Koglin et al., 2003).
FIGURE 3 | Relevant amino acids in pNPYAla-scan at NPY receptors. Positions in blue represent the amino acids showing a high impact when exchanged
to Ala (Beck-Sickinger et al., 1994).
agonists have been synthesized in the past. Interestingly, in con-
trast to all otherY receptors,Y2 receptors allow large truncations of
the peptidic ligands without loss of afﬁnity (Beck-Sickinger and
Jung, 1995) and also cyclizations between N- and C-terminally
located residues are tolerated (Kirby et al., 1993b). Most com-
monlyusedY2 receptor selectiveNPY-analogs are theN-terminally
truncated NPY(3–36) and NPY(13–36). Even larger N-terminal
truncations and centrally truncated analogs can bind to the Y2
receptor with nanomolar afﬁnity [e.g., NPY(18–36), NPY(22–36),
[Ahx5−24]NPY; Figure 1B; Beck et al., 1989; Fournier et al., 1994;
Beck-Sickinger and Jung, 1995; Keire et al., 2000b]. An Ala-scan of
the complete NPY peptide revealed only few positions to be highly
important (Figure 3).
The substitution of Pro5 to Ala led to a 600-fold loss of afﬁnity.
Accordingly, all other important residues except Pro5 are located
in the C-terminal part of NPY. The individual substitution of
Arg19, Tyr20, Tyr27, and Asn29 in the NPY peptide showed a 30- to
40-fold lower afﬁnity. A more dramatic effect could be observed
for the residues Leu31 (1000-fold lower afﬁnity), Arg33 (1350-
fold),Gln34 (150-fold),Arg35 (75000-fold), andTyr36 (17500-fold;
Figure 3; Cabrele and Beck-Sickinger, 2000; Eckard et al., 2001).
Interestingly, the introduction of a Pro residue at position 34 is
not tolerated at the Y2 receptor, which is in contrast to the effect
observed on the other Y receptor subtypes (Beck-Sickinger et al.,
1994; Keire et al., 2000b; Eckard et al., 2001). Although Tyr36 may
not be substituted by Ala, the introduction of Hty (homotyro-
sine) or p-substituted Phe in PYY(3–36) is well tolerated at the
Y2 receptor, but almost completely abolishes binding of the mod-
iﬁed NPY analogs at Y1 or Y4 receptors (Pedersen et al., 2009).
Taken together, these data underline the importance of the C-
terminal part of the peptide ligand for high-afﬁnity binding to the
Y2 receptor, despite the fact that the binding pocket for NPY at
the Y2 receptor seems to be less narrow than the ones of Y1 or Y4
receptors.
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FIGURE 4 | Non-peptidic antagonists forY1 andY4 receptors. (A) Antagonists for theY1 receptor (Rudolf et al., 1994; Hipskind et al., 1997;Wieland et al.,
1998; Balasubramaniam et al., 2001; Sjodin et al., 2006; Antal-Zimanyi et al., 2008); (B) Antagonists for theY4 receptor (Ziemek et al., 2007).
A number of selective high-afﬁnity antagonists at the Y2 recep-
tor have been published so far. The most widely used compound
in pharmacological studies is BIIE0246 (Figure 5A; Doods et al.,
1999). In order to identify compounds with improved biostabil-
ity, bioavailability, and brain permeability, further studies have
been conducted. A number of molecules and scaffolds have been
reported as highly selective and afﬁne small molecule Y2 recep-
tor antagonists (Figure 5A) including JNJ-527787 (Bonaventure
et al., 2004; Jablonowski et al., 2004), SF-11, SF-21, SF-22, SF-31,
SF-41 (Brothers et al., 2010), ML072 to ML075 (Saldanha et al.,
2009), JNJ-31020028 (Shoblock et al., 2010; Swanson et al., 2011),
a series of substituted 3-chloranilides (Lunniss et al., 2009, 2010),
CYM 9484, and CYM 9552 (Mittapalli et al., 2012).
Y4 RECEPTOR
The Ala-scan of the NPY (Eckard et al., 2001) revealed that again
Arg33 and Arg35 are crucial for receptor afﬁnity. Ala substitutions
in these positions led to a dramatic loss in binding. Positions
FIGURE 5 | Non-peptidic antagonists ofY2 andY5 receptors. (A)Y2 receptor antagonists (Doods et al., 1999; Saldanha et al., 2009; Shoblock et al., 2010;
Swanson et al., 2011); (B)Y5 receptor antagonists (Criscione et al., 1998; Kanatani et al., 2000a; Rueeger et al., 2000; Kakui et al., 2006).
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Tyr20, Tyr27, Arg25, Thr32, and Tyr36 are also important residues
in the ligand and showed a loss in binding afﬁnity (30- to 60-fold),
whereas Pro5, Pro8, and Tyr21 proved to be less relevant, causing
only a slight loss in afﬁnity (5- to 10-fold) when changed to Ala
(Figure 3).
In a follow-up study using hPP (Merten et al., 2007), Arg
residues 33 and 35 were conﬁrmed to be essential for receptor
activation, showing a dramatic effect when exchanged to Ala in
position 33. Position Arg35 was found to interact with Asp6.59 of
the receptor.
Because this receptor subtype has its own selective ligand, pep-
tide research is more focused on improving proteolytic stability
and increasing bioavailability of the peptide. However, a number
of speciﬁc ligands have been published in the past years for this
receptor. As previously described, position 34 of NPY peptides
is a key residue to introduce Y4 receptor selectivity to NPY and
PYY, whereas in PP when exchanging Pro34 for Gln the peptide
acquires Y2 agonistic properties without losing Y4 receptor activ-
ity. Some of the analogs published like [Gln34]-hPP, the so called
Obinepitide (Schwartz, 2006), which is selective for Y2 and Y4
receptors, contains this exchange (Figure 1C). Other small pep-
tide agonists described also as Y1 receptor antagonists are: GR23-
1118 (1229U91 or GW1229), T-241, and T-190 (Figure 2; Schober
et al., 1998).
To our knowledge, only one ligand with antagonistic proper-
ties at the hY4 receptor has been published up to now. UR-AK49
(Figure 4B) is a weak hY4 receptor antagonist but unselec-
tive, because it can also bind to hY1 and hY5 receptors (Ziemek
et al., 2007).
Y5 RECEPTOR
The hY5 receptor subtype does not tolerate large truncations of
NPY. While the deletion of the ﬁrst amino acid is accepted by
the hY5 receptor, further N-terminal truncation of NPY results
in a decreased afﬁnity of the peptides. Similarly, larger central
truncations of NPY are not tolerated by Y5 receptors. The only
centrally truncated analog of NPY with high Y5 receptor afﬁnity is
[Ahx9−17]pNPY with a ∼15-fold decreased afﬁnity compared to
pNPY (Cabrele and Beck-Sickinger, 2000).
An Ala scan of the complete peptide revealed the Pro residues
2, 5, and 8 to be important for the afﬁnity of NPY at the Y5
(Figure 3). Haack et al. (2008) could conﬁrm the importance of
the peptideN-terminus for high-afﬁnity binding at theY5 receptor
by a pyridone dipeptide scan. In addition to these ﬁndings, the
individual substitution of Tyr residues 20, 21, 27, and 36 to Ala
led to a loss of afﬁnity; Arg25 was also shown to be important for
the ligand afﬁnity. The highest impact could be observed for Tyr27
(∼400-fold) and Arg35 (1000-fold; Cabrele and Beck-Sickinger,
2000), these ﬁndings ﬁt with the fact that these two positions are
involved in interactions with the receptor.
A number of selective high-afﬁnity analogs of NPY and PYY
have been developed in the past. It has been shown that espe-
cially the substitution of position 32 of the peptide ligands is
critical for Y5 selectivity (Figure 1A). [D-Trp32]NPY and [Ala31,
Aib32]NPY have been reported to be highly selective and potent
agonists of Y5 receptor (Parker et al., 2000; Cabrele et al., 2002).
However, themost potent and selective activator of theY5 receptor
subtype is a chimeric peptide derived from chicken PP, human
NPY, and human PP ([cPP1−7, NPY19−23, His34]hPP; Cabrele
and Beck-Sickinger, 2000). In addition, Y5 receptors display
high-afﬁnity to some NPY analogs which also have a consider-
able afﬁnity for other Y receptor subtypes. [Leu31,Pro34]pNPY
is a Y1/Y4/Y5 selective agonist (Fuhlendorff et al., 1990; Wid-
dowson et al., 1997), whereas the deletion of the ﬁrst Tyr
residue results in the Y2/Y5 selective agonist NPY (2–36) (Gerald
et al., 1996).
Since NPY has been shown to stimulate feeding via the Y5
receptor, intensive research has been performed to identify small
molecule antagonists of the humanY5 receptor as potential feeding
suppressors. The ﬁrst compound that was published as an antago-
nist of Y5 receptor was CGP71683A (Figure 5B), which displayed
high-afﬁnity and selectivity at the rY5 receptor (Criscione et al.,
1998). Later studies conﬁrmed the high-afﬁnity and selectivity also
for the hY5 receptor subtype (Rueeger et al., 2000). Other selec-
tive small antagonists at the human Y5 receptor include L152,804
(Kanatani et al., 2000a), FMS586 (Kakui et al., 2006), MK-0557
(Erondu et al., 2007), and SCH 500946 (Mullins et al., 2008). In
the last 5 years, more than 10 studies have been published pre-
senting newly identiﬁed or improved small molecule antagonists
of the Y5 receptor. This clearly shows the importance of the Y5
receptor as an anti-obesity target.
HOW TO IDENTIFY RELEVANT RESIDUES ON THE RECEPTOR
FOR BINDING AND SUBTYPE SELECTIVITY
GENERAL STRATEGIES
As these receptors consist of 350–450 residues it is impossible to
perform a single mutagenesis approach to investigate each amino
acid. In order to overcome this problem chimeric receptors can be
used, in which fragments of a receptor (e.g., extracellular loops or
transmembrane helices) can be exchanged between receptor sub-
types. Testing these new constructs with the main agonist from
both receptor subtypes can provide information about the impor-
tance of one or the other segment, in terms of interaction with
the ligand. As soon as an important area in a receptor has been
identiﬁed, a more detailed study can be carried out using single
andmultiplemutants, where certain residues of a receptor subtype
are exchanged by the ones present on the other receptor subtype
of investigation. This strategy allows to ﬁnd amino acids that may
play a role in selectivity to a certain agonist.
When investigating the relevance of the N-terminus, succes-
sive truncations or substitutions using tags or spacers can be an
elegant method. Furthermore, C-terminal truncations can pro-
vide information about segments relevant for internalization. It
is known that this receptor part is involved in arrestin-dependent
internalization processes of Y1,Y2, andY5 receptors (Walther et al.,
2011). However, single mutagenesis techniques can be used to
investigate important residues for the structure or for ligand recep-
tor interactions. Using this approach, certain residues located in
extracellular areas of the protein aremutated toAla or other amino
acids in single substitutions. The residues can be chosen accord-
ing to its location, charge, aromaticity, hydrophobicity. Moreover,
3-D models are also a good tool to select new targets, although
mutagenesis data are needed to reﬁne the models and make them
more reliable. Once a relevant residue has been identiﬁed, double
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cycle mutagenesis can be used to ﬁnd the type of interaction that
includes both positions. In this technique, peptide analogs con-
taining modiﬁcations in positions of interest are investigated with
receptor mutants. The aim is to form artiﬁcial bonds to proof a
native interaction. The introduction of charged residues in the
peptide and receptor positions to create a repulsion/attraction, or
aromatic residues and hydrophobic residues are feasible ways to
prove a ligand receptor interaction. In order to ﬁnally prove a
ligand-receptor interaction, a reciprocal mutation approach can
be followed, where the residue of interest on the peptide side
is exchanged by the residue present on the receptor side and
vice versa. In the case of a critical position or segment, the bind-
ing afﬁnity of the native ligand should signiﬁcantly decrease,
whereas in signal transduction assays the EC50 or half maximal
activation value should increase. Despite all the advantages that
these approaches provide, it has to be taken into account that
they also present some disadvantages. Thus, when constructing
receptor chimeras or receptor mutants, alterations in the receptor
structure may arise due to misfolding and therefore may lead to
impaired receptor export. Moreover, these modiﬁcations might
result in a reduced receptor retention time at the cell surface
and an enhanced degradation. All together, this might lead to
a loss in binding or receptor activity. In order to analyze such
phenomena, ﬂuorescence microscopy, cell surface ELISA or radi-
oligand binding studies are a good tool to ensure cell surface
expression.
Y1 RECEPTOR
In the past years, much effort has been made to characterize this
receptor. Using N-terminal truncations and receptor chimera, it
could be elucidated that the N-terminal part of NPY receptors
does not participate in the binding pocket. N-terminal truncation
in the hY1 receptor disrupts the membrane expression; however
any eight residues are enough to recover themembrane expression
(Lindner et al., 2009).
From all these studies, a number of residues emerged as impor-
tant for the receptor. First of all, two negatively charged residues
are able to establish electrostatic interaction. Asp2.68 and Asp6.59
were found to be important for the receptor as the peptide loses
afﬁnity when mutated to Ala (Sautel et al., 1995, 1996; Kannoa
et al., 2001; Sjodin et al., 2006). Furthermore Asp6.59 was shown
to bind Arg35 of pNPY being the ﬁrst and only proved interac-
tion for this receptor (Merten et al., 2007). Other residues that
appeared to be important in several studies are Tyr2.64, Phe6.58,
and His7.31 (Sautel et al., 1995, 1996; Kannoa et al., 2001; Sjodin
et al., 2006), although a direct interactionwas never established for
any of the amino acids of the ligand. It was suggested that these
residues form a hydrophobic pocket in the receptor. Further inves-
tigations using the Y1 receptor antagonist BIBP 3226 showed that
Tyr2.64 and His7.31 did not affect the conformation of the receptor
in a major way (Sautel et al., 1996) as the antagonist was perfectly
bound. Taken together, it is very likely that position 6.58 and 7.31
interact with a C-terminally located amino acid, on the other hand
it is unlikely that Tyr2.64 interacts with the C-terminus as it seems
to be too far from the other two residues.
Other relevant residues of the receptor are Trp6.60, Asn6.55, and
Asn7.32 (Kannoa et al., 2001). Although position 6.55 is in a slightly
deeper position, Asn6.55 and Asn7.32 showed a loss in PYY binding
and also in antagonist binding suggesting that they could play a
role in ligand binding (Figure 6A).
Studies with antagonists indicate that the binding of these com-
pounds differs depending on the ligand between transmembrane
helices 3 and 7. Taking all the data into consideration, it can be
assumed that the binding pattern of the native ligands and the
small antagonists overlaps in TM6 because several residues have
been found to be relevant in both cases.
Y2 RECEPTOR
In this receptor subtype, the N-terminus does not play a role in
membrane expression and it does not participate in a subtype spe-
ciﬁc binding pocket. However, it does play a role in agonist induced
internalization processes since the complete truncation slowed
down the process, although it could be seen that the exchange
of the N-terminal fragment by the hY1 receptor or hY5 receptor
fragment did not affect ligand dependent internalization (Lindner
et al., 2009).
Mutagenesis studies to identify residues that contribute to
ligand binding in the Y2 receptor were initially motivated by
the ﬁnding that human and chicken Y2 receptors show a sig-
niﬁcantly different pharmacological proﬁle. The chicken Y2
receptor is able to bind [Leu31,Pro34]-NPY, a peptide agonist
selective for mammalian Y1/Y4/Y5 receptors, but was unable
to bind BIIE0246, a small molecule antagonist for mammalian
Y2 receptors (Salaneck et al., 2000). Sequence comparison and
reciprocal mutagenesis revealed three residues in transmembrane
helices 3, 5, and 6 that contribute to the binding of BIIE0246.
Individual and combined substitution of Gln3.37, Leu5.51, and
Leu6.51 in the hY2 receptor decreased the afﬁnity for BIIE0246
to a chY2-like level, whereas substitution of the corresponding
residues in the chY2 by the human residues increased the afﬁn-
ity for BIIE0246 (Berglund et al., 2002). Further mutagenesis
studies on the human Y2 receptor revealed interaction part-
ners for the native peptidic ligand NPY. Several acidic residues
have been tested for their importance for NPY binding. Glu5.27
and Asp6.59 turned out to be highly important for the bind-
ing of NPY (Figure 6C). While Asp6.59 is important for all Y
receptor subtypes, Glu5.27 only plays a role in the Y2 recep-
tor. Both receptor mutants were tested in a signal transduction
assay using pNPY, [Ala25]pNPY, [Ala33]pNPY, and [Ala35]pNPY
to identify the interaction partner of the two acidic residues
in the peptide. It could be shown that Asp6.59 interacts with
Arg33 of the peptidic ligand in the Y2 and Y5 receptors, whereas
the interaction partner in Y1 and Y4 receptors is Arg35. How-
ever, no direct interaction partner could be identiﬁed for Glu5.27
(Merten et al., 2007). More recent studies investigated additional
residues in the Y2 receptor for their impact on the binding
of pPYY, pNPY, hPYY (3–36), pNPY(13–36), and the non-
peptidic antagonist BIIE0246 (Akerberg et al., 2010; Fallmar et al.,
2011). The residues tested, namely Tyr2.64, Gly2.68, Thr3.40,
Leu4.60, Gln6.55, Val6.58, and Tyr7.31, were chosen by similar-
ity to residues in the Y1 receptor subtype, which were proven
to be important for ligand binding in this receptor subtype.
It could be shown, that of the tested residues, only Tyr2.64
participates in the binding of all tested peptidic ligands and
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FIGURE 6 | Binding mode of NPY receptors. (A) hY1 receptor binding mode (Sautel et al., 1995, 1996; Kannoa et al., 2001; Sjodin et al., 2006; Merten et al.,
2007); (B) hY4 receptor binding mode (Merten et al., 2007); (C) hY2 receptor binding mode (Merten et al., 2007; Akerberg et al., 2010); (D) hY5 receptor binding
mode (Merten et al., 2007; Lindner et al., 2008b).
the non-peptidic antagonist BIIE0246. The substitution of this
residue to Ala resulted in a ﬁve- to ninefold reduction in afﬁnity
(Akerberg et al., 2010).
The individual substitution of Tyr7.31 by Ala and Gly2.68 by
the bigger and more polar residue Asn revealed a lower afﬁnity
only for the truncated peptide agonists. The authors hypothe-
size that Tyr7.31 does not play a role in binding of the full-length
peptide, but may contribute to a compensatory interaction for lig-
ands that lack the N-terminal residues. Furthermore, the authors
could show that an introduction of a His residue in position 7.31
(the corresponding residue in Y1 receptor) completely abolished
the binding of [125I]-pPYY (Akerberg et al., 2010). These ﬁnd-
ings are somewhat unexpected, since this His residue was shown
to be involved in ligand binding in the Y1 receptor (Sjodin et al.,
2006). This indicates that position 7.31 is important in both recep-
tor subtypes, but may have different modes of action (Akerberg
et al., 2010). For position 2.68, a mode of binding is proposed in
which the lack of Asp (a residue common to all other Y receptor
subtypes at this position) contributes to the selectivity of trun-
cated peptides [e.g., NPY(3–36)] for theY2 receptor (Fallmar et al.,
2011). The Leu4.60Ala mutant showed a slightly decreased afﬁnity
for hPYY(3–36) and a strong loss of afﬁnity for BIIE0246, which
may be caused by a weakened or lost hydrophobic interaction.
This indicates that this residue is highly important for antago-
nist binding. The corresponding position in Y1 receptor (Phe4.60)
has been shown to be involved in the binding of [125I]NPY,
[3H]BIBP3226 (Sautel et al., 1996) as well as [3H]J-104870 (Kan-
noa et al., 2001). This indicates that position 4.60 is involved in the
binding of small molecule antagonists at both receptor subtypes,
Y1 and Y2.
The Y2 receptor mutants Thr3.40Ile and Gln6.55Ala showed
increased afﬁnity for pNPY and hPYY(3–36), but decreased afﬁn-
ity for the non-peptidic antagonist BIIE0246. Taken into account
that these positions are located deeper in the transmembrane part
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of the receptor, an indirect effect on the binding of peptidic lig-
ands would be themost likely explanation. However, the decreased
binding of BIIE0246 may be also explained by a different binding
pocket for small molecule antagonists, located more deeply in the
transmembrane (Fallmar et al., 2011) and surrounded not only by
Thr3.40 and Gln6.55, but also by the nearby residue Gln3.37, which
was earlier shown to participate in the binding of BIIE0246 earlier
(Berglund et al., 2002).
Y4 RECEPTOR
N-terminal truncations and substitutions revealed the importance
of this fragment for membrane expression and indicated that the
N-terminus is not involved in forming a speciﬁc binding pocket. It
is likely that this part could stabilize the TM1 to ensure the correct
receptor structure (Lindner et al., 2009).
Two positions were investigated to ﬁnd the binding partners on
the ligand side (Merten et al., 2007). Glu5.24 was mutated to Ala in
order to test the inﬂuence of the side chain, Glu5.24Ala showed a
threefold loss in potency. On the other hand, Asp6.59 was mutated
to Ala, Glu, Asn, and Arg to test the inﬂuence of charge and length
of the side chain. The mutation to Ala showed a complete loss
of both binding and activity, the exchange to Glu displayed wild-
type-like binding and activation. In addition, the mutation to Asn
showed indeterminate binding and a 200-fold loss in activation.
Finally the exchange to Arg resulted in a dramatic loss in potency
(>600-fold) and in no detectable binding (Figure 6B).
Y5 RECEPTOR
The Y5 subtype N-terminus could play a role in ligand binding,
since the partial truncation of the segment produced a loss in acti-
vation. Interestingly, the receptor remains on the membrane even
when the complete N-terminus is removed (Lindner et al., 2009).
Only fewmutagenesis studies have been published so far for the
human Y5 receptor. Merten et al. (2007) exchanged three acidic
residues in the extracellular domains of Y5 receptor. While the
Asp6.62Ala mutant showed wild-type-like pharmacological prop-
erties, Asp6.59Ala and Glu5.27Ala displayed a dramatically reduced
afﬁnity for NPY. Additional residues were investigated by Lindner
et al. (2008b), resulting in identiﬁcation of a third acidic residue
(Asp2.68) which is important for ligand binding at the Y5 recep-
tor. These Ala-mutants have also been tested with NPY analogs in
which theTyr27, Tyr36, and the Arg residues at position 25, 33, and
35were individually substituted byAla (Figure 6D). This approach
revealed no further loss of afﬁnity for [Ala33]pNPY on the
Asp6.59Ala mutant of the receptor, indicating a direct interaction
betweenAla33 of the peptide andAsp6.59 of the receptor. Similarly,
Arg25 of the NPY peptide could be identiﬁed as the interaction
partner for Asp2.68 of the receptor (Lindner et al., 2008b).
CONCLUSION AND PERSPECTIVES
The NPY system has been extensively characterized in the last
years. The modulation of actions mediated by the distinct recep-
tors like, e.g., its involvement in obesity, cancer, and epilepsy
are of great importance. Therefore, the development of receptor
subtype-selective ligands and structure-activity relationship stud-
ies have been a major objective in the past years. Primarily, amino
acid scans and truncations have identiﬁed the important residues
and areas of the ligand with respect to binding at each receptor.
The Y receptors have been extensively studied, several important
residues have been characterized and some of the binding pockets
have been partially characterized. Two subtype-selective interac-
tions have been elucidated so far. A similar bindingmode has been
identiﬁed on NPY receptors, where a common residue Asp6.59
binds to one of the two C-terminally located Arg of the peptide
depending on the receptor subtype. Moreover, a second bind-
ing interaction has been found on the Y5 receptor where Asp2.68
located at the top of TM2 interacts with Arg25 of the peptide
(Merten et al., 2007; Lindner et al., 2008b). This ﬁnding would
suggest that probably a second interaction could take place in
other receptor subtypes. Nevertheless, further investigations have
to be performed. It is likely that more interactions between the
receptors and the peptides could occur, therefore structure activity
relationship studies are still a focus of interest.
The design of short analogs and antagonists have conﬁrmed
these ﬁndings, indicating that this is a great tool to modulate
and study the receptors. Some promising progresses have been
achieved in cancer diagnosis using Y1 receptor selective short lig-
ands. However the development of short analogs for treatment of
this pathology still remains challenging. Also in anti-obesity drugs,
Y2/Y4receptor selective agonists are in progress and currently in
clinical trials of Phase I/II. On the basis of well studied character-
istics accounting for receptor subtype selectivity, it is likely that
subsequent investigations could be focused on the improvement
of pharmacological properties such as stability and half-life. In
addition the development of more potent selective ligands might
be a focus of interest.
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